Kidney Cancer

You can now review and comment on this draft guideline.

The consultation closes on Tuesday 28^th October 2025 at 5pm.

How to comment

1. Register your organisation or comment as an individual

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.

Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.

We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.

2. Read the consultation documents

Documents to comment on:

• Draft guideline 
• Equality and health inequalities assessment 

Clinical evidence:

• Evidence review A: surgery for localised RCC
• Evidence review B: non-surgical interventions
• Evidence review C: surgery for locally advanced RCC
• Evidence review D: information needs
• Evidence review E: active surveillance
• Evidence review F: follow up
• Evidence review G: heritable RCC
• Evidence review H: managing advanced RCC
• Evidence review I1: CT and MRI
• Evidence review I2: other imaging
• Evidence review J: biopsy
• Evidence review K: risk prediction
• Evidence review L: metastatic risk prediction
• Methods

Economic evidence:

• Economic report: management costing analysis
• Economic report: follow up model
• Cost-effectiveness model for management and follow up (available on request)
• Costing analysis (available on request)

If you want to review the economic model or costing analysis, please see 5. Economic models below and fill in the confidentiality form.

Visual summaries:

• Systemic anticancer therapy for advanced renal cell carcinoma: treatment options (intermediate or poor risk IMDC):
  • Visual summary
  • Accessible version
• Systematic anticancer therapy for advanced renal cell carcinoma: treatment options (favourable risk IMDC):
  • Visual summary
  • Accessible version

Other information about the consultation

• Committee membership list
• Register of interests
• Acknowledgements
• Developing NICE guidelines: how to get involved
• Final scope – for information

3. Add your comments

• You must use this Comments form
• You must declare any links with, or funding from, the tobacco industry

If you share similar views with another organisation, send a joint response.

Make sure you consider:

• The areas that will have the biggest impact on practice and be challenging to implement
• How to help users overcome challenges
• Developing NICE guidelines: how to get involved suggests some other areas to comment on.

4. Email the form to us

Email: [email protected]  

Deadline: Tuesday 28^th October 2025 at 5pm

5. Economic model

The developer has produced an economic model to support the guideline on Kidney Cancer. To receive an executable version of this model or the costing analysis, please submit a request to [email protected]  with a signed copy of the confidentiality acknowledgement and undertaking form.

We will then send you a link to an executable version of the economic model by email. The deadline for returning your comments is the same as for the guideline consultation: Tuesday 28^th October 2025 at 5pm.

6. Quality Standard

The consultation on the draft quality standard to support this guideline is also now open.

Please see the consultation webpage for further information.